Successful immunotherapy responses in cancer patients often relies on a high accumulation of tumour-infiltrating lymphocytes (TILs) which makes cancer cells more susceptible to type 1 T helper cell IFN-γ-mediated anti-tumour immune responses (Zipeto et al., 2016). Here, IFNG is linked to cancer.